Endocare Horizon urology stent clinicals to be under way in first half of 1998, CEO tells investors.
This article was originally published in The Gray Sheet
Executive SummaryENDOCARE UROLOGY STENT CLINICALS ON HORIZON FOR FIRST HALF OF 1998, Paul Mikus, chairman and CEO, stated at an Oct. 29 session of the Oppenheimer & Co. health care conference in New York City. The Horizon stent studies will evaluate the device in preventing urine retention caused by swelling after thermal treatment of benign prostatic hyperplasia.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.